comparemela.com

Latest Breaking News On - Mike brophy - Page 8 : comparemela.com

Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in JCO Precision Oncology.

Texas
United-states
California
San-carlos
Lesley-bogdanow
Mike-brophy
Natera-inc
Clinical-laboratory-improvement-amendments
Corporate-communications
Nasdaq
National-comprehensive-cancer-network
Breakthrough-device-designations

Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and.

California
United-states
San-antonio
Texas
San-carlos
Lesley-bogdanow
Mike-brophy
Natera-inc
Clinical-laboratory-improvement-amendments
Nasdaq
Antonio-breast-cancer-symposium
Minetta-liu

Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication in Prenatal Diagnosis of a clinical.

California
United-states
Kalyan
Maharashtra
India
Texas
San-carlos
Lesley-bogdanow
Sheetal-parmar
Mike-brophy
Herman-hedriana
Natera-inc

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike.

California
United-states
Texas
San-carlos
Lesley-bogdanow
Mike-brophy
Piper-sandler
Steve-chapman
Natera-inc
Clinical-laboratory-improvement-amendments
Corporate-communications
Nasdaq

New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which.

California
United-states
Texas
San-carlos
Lesley-bogdanow
Mike-brophy
Natera-inc
Clinical-laboratory-improvement-amendments
Corporate-communications
Nasdaq
Nature-medicine
Minetta-liu

vimarsana © 2020. All Rights Reserved.